PATENT CLAIM ANALYSIS

Application Number: 16072291
Application Type: Utility
Filing Date: 2018-07
Publication Date: 2018-12
Patent Classification: ["514", "146000"]

Abstract:
The present invention is directed to novel cytotoxic tubulysin analogs and derivatives, to antibody drug conjugates thereof, and to methods for using the same to treat medical conditions including cancer.

Claim (Index 28):
A method for killing or inhibiting the proliferation of tumor cells or cancer cells comprising treating tumor cells or cancer cells in a patient with an amount of the compound of  claim 17 , or a pharmaceutically acceptable salt or solvate thereof, said amount being effective to kill or inhibit the proliferation of the tumor cells or cancer cells.

Metadata:
- Claim Count in Document: 7.0
- Percentile: 95.0
- Lexical Diversity: 1.17857
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14793942', '13670612', '14322262', '14069057', '15280563']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7495727461073002
- 35 USC 102 Novelty (BERT): 0.5292981747023412
- Combined Prediction Score: 0.7275452889668044
- Mean Citation Score: 318.400396
- Max Citation Score: 330.31903
- Similarity Product: 234.1970163538837

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test